3692 — Hansoh Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$192.43bn
- HK$153.55bn
- CNY15.03bn
Brief: Hansoh Pharmaceutical Issue Of Hk$4,680 Million Zero Coupon Convertible Bonds Due 2033
China's Hansoh Pharmaceutical launches $600 million convertible bond, term sheet shows
Brief: Hansoh Pharmaceutical Reports Drug Registration Approval Of 5th Indication Of Ameile Granted By NMPA
Factbox: Top pharma companies racing to launch first weight-loss pill
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Hansoh Pharmaceutical Says Unit Enters License Agreement With Glenmark For Aumolertinib
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Hansoh Pharmaceutical Says China's Nmpa Accepts NDA For Hs-10365 Capsules
Swiss stocks - Factors to watch on October 17
Refile: BUZZ-China's Hansoh Pharma rises on Roche licensing deal
Brief: Hansoh Pharmaceutical Enters License Agreement With Roche
China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche (updated)
China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche
Hansoh leads slide in HK-listed biotech shares on report of US curbs
Brief: Hansoh Pharmaceutical Receives Drug Registration Approval Of Second Indication Of Xinyue (Inebilizumab Injection) By NMPA
Factbox: Top pharma companies work to launch first weight-loss pill